Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial

BACKGROUND: In ALTER 1202, anlotinib prolonged the progression-free survival (PFS) and overall survival (OS) of patients with relapsed small cell lung cancer (SCLC). The aim of this study was to explore the effect of front-line thoracic radiotherapy (RT) on the benefits of anlotinib as a third-line-...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Cheng, Ying, Li, Kai, Shi, Jianhua, Liu, Ying, Wu, Lin, Han, Baohui, Chen, Gongyan, He, Jianxing, Wang, Jie, Qin, Haifeng, Li, Xiaoling, Hamaji, Masatsugu, Park, Henry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512470/
https://www.ncbi.nlm.nih.gov/pubmed/34733629
http://dx.doi.org/10.21037/tlcr-21-632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512470/
https://www.ncbi.nlm.nih.gov/pubmed/34733629
http://dx.doi.org/10.21037/tlcr-21-632

Ejemplares similares